Literature DB >> 12763399

Medical management of obesity: present and future therapy.

Samuel Klein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12763399     DOI： 10.1016/S1091-255X(03)00049-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


× No keyword cloud information.
  20 in total

1.  Reduction in blood cyclosporine concentrations by orlistat.

Authors:  E Colman; M Fossler
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

2.  Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes.

Authors:  B Schnetzler; M Kondo-Oestreicher; D Vala; G Khatchatourian; B Faidutti
Journal:  Transplantation       Date:  2000-11-27       Impact factor: 4.939

3.  Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.

Authors:  W P James; A Astrup; N Finer; J Hilsted; P Kopelman; S Rössner; W H Saris; L F Van Gaal
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

4.  Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.

Authors:  M Apfelbaum; P Vague; O Ziegler; C Hanotin; F Thomas; E Leutenegger
Journal:  Am J Med       Date:  1999-02       Impact factor: 4.965

5.  One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.

Authors:  N Finer; W P James; P G Kopelman; M E Lean; G Williams
Journal:  Int J Obes Relat Metab Disord       Date:  2000-03

6.  Orlistat in the long-term treatment of obesity in primary care settings.

Authors:  J Hauptman; C Lucas; M N Boldrin; H Collins; K R Segal
Journal:  Arch Fam Med       Date:  2000-02

7.  Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.

Authors:  T A Wadden; R I Berkowitz; D B Sarwer; R Prus-Wisniewski; C Steinberg
Journal:  Arch Intern Med       Date:  2001-01-22

8.  Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers.

Authors:  J Zhi; A T Melia; R Guerciolini; J Chung; J Kinberg; J B Hauptman; I H Patel
Journal:  Clin Pharmacol Ther       Date:  1994-07       Impact factor: 6.875

9.  Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Authors:  P A Hollander; S C Elbein; I B Hirsch; D Kelley; J McGill; T Taylor; S R Weiss; S E Crockett; R A Kaplan; J Comstock; C P Lucas; P A Lodewick; W Canovatchel; J Chung; J Hauptman
Journal:  Diabetes Care       Date:  1998-08       Impact factor: 19.112

10.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272
View more
  1 in total

1.  Prospective single-site case series utilizing an endolumenal tissue anchoring system for revision of post-RYGB stomal and pouch dilatation.

Authors:  Frank Borao; Steven Gorcey; Aaron Capuano
Journal:  Surg Endosc       Date:  2010-03-04       Impact factor: 4.584
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.